Keryx Biopharmaceuticals Inc
KERX
KERX was delisted on the 12th of December, 2018.
130 hedge funds and large institutions have $312M invested in Keryx Biopharmaceuticals Inc in 2016 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 49 increasing their positions, 40 reducing their positions, and 15 closing their positions.
23% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 40
13% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 15
2% more funds holding
Funds holding: 128 → 130 (+2)
4% less call options, than puts
Call options by funds: $3.09M | Put options by funds: $3.22M
16% less capital invested
Capital invested by funds: $369M → $312M (-$57.7M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.22M |
| 2 |
ACM
Abrams Capital Management
Boston,
Massachusetts
|
+$875K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$797K |
| 4 |
RA
Royce & Associates
New York
|
+$439K |
| 5 |
D.E. Shaw & Co
New York
|
+$411K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$8.95M |
| 2 |
State Street
Boston,
Massachusetts
|
-$4.28M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$4.22M |
| 4 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
-$3.32M |
| 5 |
CCM
Cadian Capital Management
New York
|
-$3.03M |
KERX Hedge Fund Activity: Q1 2016 in Review
130 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in Keryx Biopharmaceuticals Inc (KERX) for Q1 2016, worth a combined $312M — down 16% from $369M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new KERX positions and 15 closed out — a net gain of 2 holders — while 49 added to existing stakes and 40 trimmed.
The largest buyer was Susquehanna International Group, adding an estimated $1.22M. The largest seller was Fidelity Investments, cutting an estimated $8.95M.
- 130 institutional investors held Keryx Biopharmaceuticals Inc (KERX) as of Q1 2016, up from 128 in Q4 2015.
- Funds reported $312M of Keryx Biopharmaceuticals Inc stock for Q1 2016, down 16% quarter-over-quarter.
- 17 funds opened new Keryx Biopharmaceuticals Inc positions in Q1 2016 and 15 closed out, a net change of +2 holders.
- The largest Keryx Biopharmaceuticals Inc buyer in Q1 2016 was Susquehanna International Group, an estimated $1.22M added.
- The largest Keryx Biopharmaceuticals Inc seller in Q1 2016 was Fidelity Investments, an estimated $8.95M sold.
Based on aggregated 13F filings for Q1 2016.